Valeant (VRX) volatility flat into upgrade to Overweight at Morgan Stanley

Valeant Pharma (NYSE: VRX) August and September call option implied volatility of 62 compares to its 52-week range of 33 to 173 into Morgan Stanley’s upgrade to Overweight and raising its price target to $42 from $33.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• AutoZone (AZO) call put ratio 1 call to 1.4 puts into quarter results
• GameStop CEO Cohen buys 1.15M shares